Journal
CLINICAL CANCER RESEARCH
Volume 18, Issue 23, Pages 6400-6406Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-11-3150
Keywords
-
Categories
Funding
- National Cancer Institute [CA58985, CA86140]
- Susan G. Komen for the Cure [KG081528]
- Howard Hughes Medical Institute [57007004]
- Radiological Society of North America [RMS1009]
Ask authors/readers for more resources
The Rad52 protein was largely ignored in humans and other mammals when the mouse knockout revealed a largely no-effect phenotype. However, using synthetic lethal approaches to investigate context-dependent function, new studies have shown that Rad52 plays a key survival role in cells lacking the function of the breast cancer type 1 susceptibility protein (BRCA1)-BRCA2 pathway of homologous recombination. Biochemical studies also showed significant differences between yeast and human Rad52 (hRad52), in which yeast Rad52 can promote strand invasion of replication protein A (RPA)-coated single-stranded DNA (ssDNA) in the presence of Rad51 but hRad52 cannot. This results in the paradox of how is hRad52 providing Rad51 function: presumably there is something missing in the biochemical assays that exists in vivo, but the nature of this missing factor is currently unknown. Recent studies have suggested that Rad52 provides back-up Rad51 function for all members of the BRCA1-BRCA2 pathway, suggesting that Rad52 may be a target for therapy in BRCA pathway-deficient cancers. Screening for ways to inhibit Rad52 would potentially provide a complementary strategy for targeting BRCA-deficient cancers in addition to poly (ADPribose) polymerase (PARP) inhibitors. Clin Cancer Res; 18(23); 6400-6. (C) 2012 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available